cancer research

A new study shows how loss of parts of the Y chromosome, a common age-related change in men's cells, can promote cancer growth. Researchers report the missing pieces help tumours evade immune defences, offering a possible explanation for why some cancers in men are more aggressive and opening paths to new treatments.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes within dense cell populations strongly influence the optimal timing of treatment cycles in cancer and antibiotic therapy. Treatment resistance is a central obstacle in both fields, and the findings suggest that scheduling therapies around these dynamics could improve outcomes. The work, associated with the Max Planck Institute for the Science of Light, points to a greater role for biophysics in designing treatment schedules.

Researchers publishing in Communications Biology report that deletions and regulatory disruption of the Y chromosome recur across cancers, suggesting loss of this chromosome may play a functional role in tumour development rather than being a harmless byproduct. The findings add to growing interest in how sex chromosome instability shapes cancer risk and progression in men.

Researchers report observing how an aggressive brain cancer physically remodels brain tissue as it grows, offering a live view of tumor progression. The findings shed light on how deadly brain tumors invade and distort surrounding structures, which could inform future treatment approaches. The work is drawing attention for its striking visualization of the disease's effects on the brain.

Coverage is circulating of the second part of a highlights roundup from the World Cancer Congress 2026, summarising key presentations and developments shared at the global oncology gathering. The roundup is aimed at cancer professionals and researchers following the congress remotely, distilling sessions into digestible takeaways. Interest centres on what new research, treatment approaches and policy discussions were featured at this year's event.

Researchers describe a 'proliferative pause' — a period when cancer cells spreading to the brain stop dividing before reactivating — and suggest this dormant phase could be a critical treatment window to stop brain metastases before they take hold. Targeting cells during this pause may prevent lethal secondary brain tumours in cancers prone to spreading there.

Volunteers and advocates with the American Cancer Society's Cancer Action Network visited Capitol Hill to meet with members of Congress, urging support for cancer research funding and patient-focused legislation. The advocacy day brings grassroots concerns about prevention, treatment access, and federal research investment directly to lawmakers, and is part of the organization's ongoing effort to keep cancer policy on the national legislative agenda.

Researchers report that biological features of prostate tumours can help determine which patients are most likely to benefit from hormone therapy. By profiling tumour biology, doctors may be able to better target treatment and avoid giving hormone therapy to those unlikely to respond, a step toward more personalised prostate cancer care.

New figures from the European Commission show that 5% of Europeans consumed alcohol every day in 2025. The statistic highlights that despite overall declines in drinking across much of the continent, a small but notable share of the population still drinks daily, a pattern linked in public health research to higher risks of liver disease, cancer and other harms. Health advocates are likely to use the data in ongoing debates over alcohol pricing, advertising and labelling rules across EU member states.

The Trump administration has committed more than $5 billion to a program called the Genesis Mission, aimed at advancing cancer research, semiconductor development, and quantum computing. The initiative signals a major federal investment in strategic technologies, combining health science goals with industrial policy on chips and next-generation computing capabilities.

Researchers have documented recurrent deletions and regulatory disruption of the Y chromosome across cancer types, according to a study published in Nature. The work suggests loss or alteration of Y chromosome genetic material may play a functional role in tumour development rather than being incidental, opening questions about how such changes influence cancer biology and potential sex-based differences in disease.